Conference Call Participants
Laura Chico – Wedbush Securities Inc., Research Division
Gregory Renza – Truist Securities, Inc., Research Division
Michael Yee – UBS Investment Bank, Research Division
Joseph Thome – TD Cowen, Research Division
Thomas Smith – Leerink Partners LLC, Research Division
Alexander Thompson – Stifel, Nicolaus & Company, Incorporated, Research Division
Faisal Khurshid – Jefferies LLC, Research Division
Rami Katkhuda – LifeSci Capital, LLC, Research Division
Lisa Walter – RBC Capital Markets, Research Division
Jin Law – Goldman Sachs Group, Inc., Research Division
Douglas Tsao – H.C. Wainwright & Co, LLC, Research Division
Derek Archila – Wells Fargo Securities, LLC, Research Division
Serge Belanger – Needham & Company, LLC, Research Division
Lachlan Hanbury-Brown – William Blair & Company L.L.C., Research Division
Brandon Frith – Wolfe Research, LLC
Presentation
Operator
Good morning, ladies and gentlemen, and welcome to the Viridian Therapeutics conference call. [Operator Instructions] As a reminder, this conference call is being recorded. I will now hand the call over to Greg Rossino, Senior Director of Investor Relations at Viridian. Please go ahead.
Greg Rossino
Thank you, operator, and good morning, everyone. Thank you for joining us to discuss the FDA approval of Lumvoa, the newly announced brand name for veligrotug-vvze for the treatment of thyroid eye disease. You can access the press release and the slides for today’s call on the Investors page of our corporate website at viridiantherapeutics.com. Before we begin, I would like to remind everyone that today’s call and webcast will contain forward-looking statements, including statements about our commercial market opportunity.
These statements are subject to risks and uncertainties that
